PRO044 SC

BioMarin Pharmaceutical · Phase 1 active Small molecule

At a glance

Generic name	PRO044 SC
Sponsor	BioMarin Pharmaceutical
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD) (PHASE1, PHASE2)
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD) (PHASE2)
Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PRO044 SC CI brief — competitive landscape report
PRO044 SC updates RSS · CI watch RSS
BioMarin Pharmaceutical portfolio CI